These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 18068807

  • 1. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H.
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [Abstract] [Full Text] [Related]

  • 2. Serotonin receptor ligands and the treatment of obesity.
    Vickers SP, Dourish CT.
    Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
    [Abstract] [Full Text] [Related]

  • 3. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
    Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):1781-95. PubMed ID: 15771424
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP.
    J Pharmacol Exp Ther; 2007 Jun 24; 321(3):1013-22. PubMed ID: 17327489
    [Abstract] [Full Text] [Related]

  • 10. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
    Ahmad S, Ngu K, Miller KJ, Wu G, Hung CP, Malmstrom S, Zhang G, O'Tanyi E, Keim WJ, Cullen MJ, Rohrbach KW, Thomas M, Ung T, Qu Q, Gan J, Narayanan R, Pelleymounter MA, Robl JA.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1128-33. PubMed ID: 20022752
    [Abstract] [Full Text] [Related]

  • 11. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P, Sohn D, Leideborg R, Caldirola P, Zlatoidsky P, Hanson S, Mohell N, Rosqvist S, Nordvall G, Johansson AM, Johansson R.
    J Med Chem; 2004 Jul 29; 47(16):3927-30. PubMed ID: 15267230
    [Abstract] [Full Text] [Related]

  • 12. The 5-HT6 receptor as a target for developing novel antiobesity drugs.
    Heal D, Gosden J, Smith S.
    Int Rev Neurobiol; 2011 Jul 29; 96():73-109. PubMed ID: 21329785
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
    Vachal P, Fletcher JM, Fong TM, Huang CC, Lao J, Xiao JC, Shen CP, Strack AM, Shearman L, Stribling S, Chen RZ, Frassetto A, Tong X, Wang J, Ball RG, Tsou NN, Hickey GJ, Thompson DF, Faidley TD, Nicolich S, Achanfuo-Yeboah J, Hora DF, Hale JJ, Hagmann WK.
    J Med Chem; 2009 Apr 23; 52(8):2550-8. PubMed ID: 19320488
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
    Jensen MD.
    Obesity (Silver Spring); 2006 Jun 23; 14 Suppl 3():143S-149S. PubMed ID: 16931496
    [Abstract] [Full Text] [Related]

  • 19. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
    Liu KK, Cornelius P, Patterson TA, Zeng Y, Santucci S, Tomlinson E, Gibbons C, Maurer TS, Marala R, Brown J, Kong JX, Lee E, Werner W, Wenzel Z, Vage C.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):266-71. PubMed ID: 19914063
    [Abstract] [Full Text] [Related]

  • 20. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.
    Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A.
    Br J Pharmacol; 1998 Jun 01; 124(3):556-62. PubMed ID: 9647481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.